Overview

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Status:
Terminated
Trial end date:
2020-04-09
Target enrollment:
Participant gender:
Summary
This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial
Phase:
Phase 2
Details
Lead Sponsor:
Stealth BioTherapeutics Inc.